ASCO Week News Summaries

Here are some other good ASCO News sources from MedAdNews:

PharmAviary provides a round up of the industry tweets of the week. Chris Truelove, editor in chief of Med Ad News and R&D Directions, scours the healthcare blogosphere to bring you a digestible summary of the big trends and issues that have everyone talking.
Updates from #ASCO, and back on the #socpharm 
Well, the American Society of Clinical Oncology meeting wrapped up this week, and there was a lot of news. A slew of companies announced clinical trial results, and there was some really good news for J&J’s Zytiga, which equaled bad news for Dendreon’s Provenge. The event also sparked discussions about how some cancer drug shortages have eased and proposed legislation to address shortages.Now that the Chicago convention center has emptied out, it’s back to the everyday grind. And the weekend awaits.

Nesting the tweets 
Some items from ASCO:

@ASCO: #ASCO12 Large cohort study reveals long-term use of TZDs associated w/ increased bladder cancer risk in type 2 diabetes ow.ly/bncTf

@BeBrightPink: Research presented at #ASCO12 shows progress in the treatment of advanced #ovariancancer ow.ly/bpGoM

@CCO_Oncology: Attend our #ASCO12 symposium on metastatic colorectal cancer ? Slides are available for download: – ow.ly/bpGV4

@CrowdRecruiter: Prostate cancer update from #ASCO12 – Dendreon, Tokai Pharma, Exelixis: ow.ly/bpqH0 #mCRPC

@CR_UK: Report from #ASCO12: is immunotherapy finally coming of age? bit.ly/NiDdL0

@CR_UK: As promised earlier, here’s an in-depth look at how we helped develop vismodegib, a new drug for basal cell skin cancer bit.ly/KY5Uep

@CR_UK: Our 2nd report from #ASCO12: a new treatment for HER2-positive breast cancer? bit.ly/KVQjMk

@CR_UK: Final report from #ASCO12: global cancer cost; helping older cancer patients; and cancer care on Facebook bit.ly/MpeteD

@harriseve: Pls B honest, Doc! It’s no failure ..if a “lowly patient” has something U haven’t seen B4 @ePatientDave #ASCO12 ow.ly/bqqhj

@hmhyltonpac: TY @drdonsdizon #ASCO12 take home 3: Social Media here to stay. Know what your patients do, be involved, provide counterbal of credible info

@jodyms: Great article by @MMarchioneAP on #ASCO12: Advanced therapies being aimed at cancer bit.ly/MqE9r8 via @reflectornews

@Ideagoras: ASCO: For Oncologists or for the Street ? worldofdtcmarketing.com/asco-for-oncol… #hcsmeu #hcsmeuES #Pharma #ASCO12

@LillyPad: Global cancer cases expected to rise 75% by 2030, acc. to @TheLancet #oncology study- from #asco12 ow.ly/boLYJ

@MaverickNY: Update on prostate cancer therapies from #asco12 – are logical combos coming next? I hope so… bit.ly/KJH3fW

@MayoClinic: From #ASCO12: Mayo Clinic study finds ginseng fights fatigue in #cancerbit.ly/KqJUuD

@MayoClinic: New drug shrinks advanced basal cell carcinoma tumors – first of its kind.newsblog.mayoclinic.org/2012/06/06/new… #skincancer

@OncLive: Dr. Eric Larsen Discusses Outcomes for AYA Patients With ALL ow.ly/bqEbk#OncLiveTV #ASCO12

@PhRMA: @KateAtPhRMA highlights the increasing # of groundbreaking #cancer meds reaching the @US_FDA onphr.ma/LvnBiV #asco12

@Xconomy: Check out what Merck’s oncology chief told Xconomy about the company’s cancer pipeline leading into #ASCO12 bit.ly/KMSNeu

Some bites from the #socpharm, #epharma, #digpharm, and #pharma streams, and elsewhere:

@CeciZak: Harvard Prof Kerfoot – studying and testing vs studying alone generates greater knowledge transfer & behavior chg #spbt2012

@CadientGroup: 4 innovative campaigns that have pushed pharma social media forward.bit.ly/M14igP #socpharm

@ChristianeTrue: All my #socpharm friends, take note of No. 5: 8 Websites you need to stop building. ow.ly/bjbYB #digpharm #epharma

@ChristianeTrue: This story from @pharmalot could have come straight from TV. “Former CRO employee stole #Merck compounds” ow.ly/bnMmw #pharma #cros

@cspenn: #BWENY @jaybaer humanity is what made blogs popular and humanity is what will keep ur blog alive. Lack of it will kill ur blog.

@Digitas_Health: Sanofi’s Data Design Diabetes Challenge is a “sweet challenge,” says @ChristianeTrue in @medadnews. pharmalive.com/magazines/meda…

@fdalawblog: Rep. Markey on J&J Decision to Stop Marketing Transvaginal Mesh Medical Device – tiny.cc/vk2ffw

@GEHealthcare: Who makes the final decision when it comes to my #cancer treatment strategy? bit.ly/IEK7Gf

@LillyPad: Regardless of #ACA outcome by SCOTUS, Lilly will advocate #patient -focused reforms. #FTushc12 More here ow.ly/boGwc

@mikermyers: iPads for everyone ow.ly/bpcDm #advertising #pharma @paliosaratoga #socialmadness

@JasonBoies: 5 Ways to Tell if Pinterest is Right For Your Businesssocialmediaexaminer.com/pinterest-for-… via @smexaminer

@marciabbrem: welcome to the dream team @bobharrell from Shire Appointed VP of Marketing for @Appature bit.ly/LF9ZSI #pharma #hcmktg #hcsm #epharma

@mchiaviello: Afraid to Speak Up at the Doctor’s Office nyti.ms/KWV0FQ #epharma

@mikecapaldi: RT @CeciZak: Duncan Lennox from Qstream says that 70% of sales reps want more customized training. Are we ready? #spbt2012?

@Reuters_Health: Corrected: Do doctor-payment sunshine laws work? reut.rs/K9874b

@SermoClient: 5 Ways Social Is Helping The #Healthcare Industry bit.ly/KBeVeS via @MediaPost #socpharm #hcsmeu

@skainfo: Generation Y nurses’ constant exposure to technology distinguishes them from previous generations nursing.advanceweb.com/Features/Artic…


Follow us on: Follow us on Twitter      
twitter.com/ChristianeTrue for Editor-in-Chief Christiane Truelove’s insights on pharma news, PR initiatives, and social media

twitter.com/MedAdNews for Med Ad Newsnews updates, exclusive content, and insights from the editors of Med Ad News

twitter.com/PharmaLive for breaking news   

U.S. on track to approve more cancer drugs in 2012 | Reuters

update@genengnewsemail.com

Comments are closed.